Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
D000740:Anemia / Q000150:complications / Q000628:therapy*; D004921:Erythropoietin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006435:Renal Dialysis; D014168:Transferrin / Q000032:analysis
D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D005293:Ferritins